Esoteric Testing Market Trends

Statistics for the 2023 & 2024 Esoteric Testing market trends, created by Mordor Intelligence™ Industry Reports. Esoteric Testing trend report includes a market forecast to 2029 and historical overview. Get a sample of this industry trends analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Trends of Esoteric Testing Industry

This section covers the major market trends shaping the Esoteric Testing Market according to our research experts:

Oncology Segment is Expected to Exhibit a Significant Market Growth Over the Forecast Period

Esoteric testing is an effective method for the detection of multiple tumor markers with high throughput, ease of operation, and low cost. Under esoteric tests, a few of the in-vitro techniques can be used for measuring antibody levels that are specific to cancers.

The oncology segment is expected to show healthy growth in the esoteric testing market during the forecast period owing to the rising importance of early diagnosis and treatment for cancer. The fecal occult blood test (FOBT) is one of the esoteric tests used to check stool samples for hidden (occult) blood. Occult blood in the stool may indicate colon cancer or polyps in the colon or rectum.

Moreover, the rise in cancer cases has increased demand for the diagnosis of diseases through esoteric testing. For instance, according to the FICCI-EY Paper, in 2022, around 19 to 20 lakh new cancer cases are estimated to be reported in India. It is tentatively predicted that the actual incidence of cancer is 1.5 to 3 times greater than what is recorded by cancer registries. Hence, it is expected to have a significant rise in esoteric tests such as fecal occult blood tests that can diagnose colon cancer, which help to drive the segment's growth over the forecast period.

Furthermore, the increasing investments in R&D activities are expected to drive the demand for testing. According to the EFPIA, in 2022, the overall R&D expenditure in the pharmaceutical industry for the European region in 2020 was recorded at approximately EUR 39,656 million (USD 411,31.20 million) and in 2021 at EUR 41,500 million (USD 43,043.80 million). This demonstrates an increase in R&D expenditure on research, which is likely to boost the development of newer esoteric tests.

Hence, the aforementioned factors are expected to boost the market growth for the cancer segment over the forecast period.

Esoteric Testing Market : Estimated Number of New Cancer Cases (In Thousand), By Sex, United States, 2022

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to be a dominant region in the esoteric testing market owing to the increasing number of R&D activities, and investments, the surge in the burden of chronic diseases, and the growing number of rare disease cases. As per the data from the NORD, around 25-30 million people were suffering from some type of rare disease in 2021. Also, almost one out of every ten individuals in America has a rare disease, and more than half of these are children. Furthermore, according to the NIH RCDC, the estimated funding for rare disease research in the United States is USD 6,191 million in 2021 and will increase to USD 6,482 million by the end of the year 2022. Thus, with the growing burden of rare diseases and increasing investment into research and development activities for rare diseases, the demand for esoteric testing is expected to increase, in turn propelling market growth in this region.

The introduction of new testing services and collaborations between major players in the region also act as drivers for the growth of the market. For instance, in January 2021, BioReference Laboratories, Inc., an OPKO Health company, introduced Scarlet Health, an in-home, fully integrated digital platform providing access to on-demand diagnostic services. Scarlet has been designed similarly to the tools consumers use daily to provide ease of use and ubiquitous convenience. Similarly, in February 2021, GRAIL, Inc. agreed with Quest Diagnostics to provide phlebotomy services to support Galleri, GRAIL's multi-cancer early detection blood test.

Likewise, in 2020, the US FDA granted a EUA to LabCorp, allowing it to test self-collected nasal swab samples from patients for coronavirus disease with its COVID-19 RT-PCR Test. While the EUA permits at-home sample collection, the testing was conducted at LabCorp's Center for Esoteric Testing, and other Clinical Laboratory Improvement Amendments (CLIA)-certified high-complexity laboratories designed by the company. All these factors are expected to augment the esoteric testing market's growth in the country.

Thus, due to the above-mentioned factors, the market is expected to witness significant growth in North America over the forecast period.

Esoteric Testing Market - Growth Rate by Region

Esoteric Testing Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)